Gemcitabine-based therapy in pancreas cancer
- 19 July 2002
- Vol. 95 (S4), 923-927
- https://doi.org/10.1002/cncr.10756
Abstract
Since its approval in 1998 by the Food and Drug Administration, gemcitabine has rapidly become accepted as a standard part of palliative therapy for patients with advanced pancreatic cancer. It has modest activity when used as a single agent, and this has led to numerous studies combining it with other active agents, including cytotoxic as well as biologic and targeted therapies. Numerous Phase II studies suggest that the combinations may have greater activity than single agent therapy. However, randomized trials concerning this are still in progress. In the current article, a variety of gemcitabine-based novel combinations showing promising activity are reviewed. Cancer 2002;95:923–7. © 2002 American Cancer Society. DOI 10.1002/cncr.10756This publication has 6 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trialBMJ, 1998
- Fatal pulmonary toxicity resulting from treatment with gemcitabineCancer, 1998
- Diffuse alveolar damage in a patient treated with gemcitabineEuropean Respiratory Journal, 1998
- Fatal pulmonary toxicity resulting from treatment with gemcitabineCancer, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997